Virtify Partners with Forte Research Systems to Optimize Regulatory Disclosure Compliance
Virtify CTRR Integrates with OnCore Enterprise Research System
Virtify, Inc., a content and regulatory information solutions for the life sciences industry, and Forte Research Systems, Inc., a leading developer of specialized clinical trial management software, announced today the integration of Forte Research Systems’ OnCore® Enterprise Research system with Virtify CTRR® (Clinical Trial Registration & Results). The integration of the two systems will optimize the submission process of clinical trials into the National Institute of Health’s clinicaltrials.gov, ensuring compliance with disclosure requirements of the Food and Drug AdministrationAmendments Act (FDAAA).
Virtify CTRR streamlines and automates the increasingly stringent mandatory registration and clinical results disclosure obligations to the National Institute of Health and other registries. Virtify CTRR eliminates duplicate data entry and polls Forte’s OnCore hourly to ensure updated data between the two systems. Coupled with the benefits of the Virtify CTRR, OnCore becomes the most comprehensive solution available for seamless compliance with clinical trial disclosure requirements.
“Virtify is pleased to partner with Forte, the acknowledged and most respected leader in clinical research management solutions for academic medical centers,” said Dr. Satish Tadikonda, president and CEO of Virtify, Inc. “OnCore is a proven system that supports streamlined management of robust portfolios of clinical trials. The Forte partnership reflects Virtify’s continued commitment to the academic medical center market, which has included a recent 3.2 version of CTRR and several academic customer wins.”
“Forte’s partnerships are driven by our customers’ needs and interests,” said Brian Wulff, Vice President of Sales, Marketing & Partnerships at Forte. “Virtify is addressing an emerging regulatory compliance issue that impacts our customers. Forte is pleased to be able to offer, in conjunction with Virtify, a market leader in regulatory information management, an integration that assists with the operational efficiency and compliance of our shared customers.”
The OnCore system is Forte's flagship product and is the result of over a decade of experience working closely with world-class research organizations. It is used by more than 50 academic medical centers, research hospitals, and cancer centers. In today's environment of growing trial complexity and regulatory oversight, the need for a centralized system has never been greater.
Learn more about the Virtify-Forte partnership at AACI Annual 2013, Washington, DC, Sept. 30-Oct.2, 2013.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
